Literature DB >> 15043209

Transmission and immunopathogenesis of FIV in cats as a model for HIV.

Mary Jo Burkhard1, Gregg A Dean.   

Abstract

The feline immunodeficiency virus (FIV) model provides a system to study lentivirus transmission, virus kinetics, pathogenesis, host responses, and immune dysfunction in a natural, out-bred host, under controlled conditions with specific-pathogen-free animals. The diversity of primary FIV strains can be exploited to mirror the range of disease manifestations associated with HIV infection. FIV is infectious via intravenous, intraperitoneal, intradermal, or subcutaneous injection as well as by atraumatic instillation onto the oral, vaginal, or rectal mucosa. Together, these features allow investigators to model specific aspects of HIV infection in a highly relevant and relatively inexpensive animal model. Well-developed areas of the FIV model include: (1) transmission of cell-associated as well as cell-free virus; (2) mucosal infectivity and immunopathogenesis; (3) vertical transmission; (4) acquired immunodeficiency including defects of the innate immune system; (5) thymic dysfunction; (6) neurotropism and neuropathogenesis; (7) host-virus interactions and the role of specific gene products; (8) efficacy of antiviral therapy; and (9) efficacy and immune correlates of experimental vaccines. This review will encompass areas specific to transmission and immunopathogenesis.

Entities:  

Mesh:

Year:  2003        PMID: 15043209     DOI: 10.2174/1570162033352101

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  68 in total

1.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Evolution of feline immunodeficiency virus Gag proteins.

Authors:  Evan Burkala; Mary Poss
Journal:  Virus Genes       Date:  2007-01-30       Impact factor: 2.332

3.  Recombination in feline immunodeficiency virus genomes from naturally infected cougars.

Authors:  Trevor C Bruen; Mary Poss
Journal:  Virology       Date:  2007-04-18       Impact factor: 3.616

Review 4.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

5.  Role of the feline immunodeficiency virus L-domain in the presence or absence of Gag processing: involvement of ubiquitin and Nedd4-2s ligase in viral egress.

Authors:  Arianna Calistri; Claudia Del Vecchio; Cristiano Salata; Michele Celestino; Marta Celegato; Heinrich Göttlinger; Giorgio Palù; Cristina Parolin
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

6.  RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus.

Authors:  Ursula Hofer; Stefan Baenziger; Mathias Heikenwalder; Erika Schlaepfer; Nadine Gehre; Stephan Regenass; Thomas Brunner; Roberto F Speck
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid.

Authors:  Samantha J McDonnel; Molly L Liepnieks; Brian G Murphy
Journal:  Antiviral Res       Date:  2014-06-02       Impact factor: 5.970

8.  Identification of a novel subtype of feline immunodeficiency virus in a population of naturally infected felines in the Brazilian Federal District.

Authors:  T G Marçola; C P C Gomes; P A Silva; G R Fernandes; G R Paludo; R W Pereira
Journal:  Virus Genes       Date:  2013-01-18       Impact factor: 2.332

9.  Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.

Authors:  Soumi Gupta; Christian M Leutenegger; Gregg A Dean; Jonathan D Steckbeck; Kelly Stefano Cole; Ellen E Sparger
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.

Authors:  Bradford K Berges; Sarah R Akkina; Joy M Folkvord; Elizabeth Connick; Ramesh Akkina
Journal:  Virology       Date:  2008-01-18       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.